Meds A-Z

Betamethasone

Detailed information about Betamethasone

Official label facts Owner quick guide first Marketing clearly labeled

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Showing simplified owner view. Switch to Vet View for full technical detail.

Pet Owner Quick Guide

Start here: what this medicine is for, what it does, and when it's usually needed.

Usually used for:

For the control of pain and inflammation associated with osteoarthritis in horses.

What it does:

When it's needed:

Call your vet sooner if you notice:

Not for use in horses intended or food. For use only by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Commonly reported reactions:

(2 reports)
(2 reports)
(1 reports)

What to ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Talk to a Vet / Find a Vet Near You

Image coming soon

Betamethasone

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Intervet, Inc.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Intervet, Inc.

Form: Gel, Injectable Suspension, Liquid (Solution), Liquid (Suspension), Ointment, Solution

Identifiers:

ANADA: 200183 ANADA: 200188 ANADA: 200229 ANADA: 200283 ANADA: 200287 ANADA: 200388 ANADA: 200415 ANADA: 200416 NADA: 113231 NADA: 132338 NADA: 140896 NADA: 141418 NADA: 141437 NADA: 34010 NADA: 34267 NADA: 46821 NADA: 49185 NDC Package: 0061-0100-01 NDC Package: 0061-0387-01 NDC Package: 0061-0387-02

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141418 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141437 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Not for use in horses intended or food. For use only by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

High: Not for use in horses intended or food. For use only by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Most Reported Reactions

Cases	Species	Serious cases
2	Cat, Dog	2
2	Cat, Dog	1
1	Cat	1
1	Dog	1
1	Dog	1
1	Dog	1
1	Dog	1
1	Dog	1

Species coverage: Cat (19) Dog (13)

View detailed reaction table

Species	Seriousness	Frequency	Reports
Cat	Non-serious	-	1
Dog	Serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Serious	-	1
Dog	Serious	-	1
Cat	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Dog	Non-serious	-	1
Cat	Serious	-	1
Dog	Non-serious	-	1
Dog	Serious	-	1
Dog	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Cat	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2020-US-055851

Storage & Handling

No storage/handling guidance is linked yet.

Source metadata: No source yet.

Documents

Official label facts are separated from secondary summaries.

Official documents: 33 • Secondary summaries: 0

Official label facts

Secondary summaries

No source yet.

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/916 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/1078 · document · Labeling
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2333/BetaVet%C2%AE · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/928 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2330/Osurnia%E2%84%A2 · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1137 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2018/GB%20Topical%20Spray · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1006 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1772 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1324/Tri-Otic%C2%AE%20Ointment · document · SPL

Promotional Materials (Marketing)

This content is marketing material and not clinical guidance.

No marketing assets are linked yet.

No source yet.

Source metadata: No source yet.

Talk to a Vet / Find a Vet Near You

Technical appendix (vet reference)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
Animal Drugs @ FDA: Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Feb 9, 2026, 3:13 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: BetaVet® Betagen™ Topical Spray Betasone Aqueous Suspension Betavet Soluspan Suspension GB Topical Spray GBC Ointment™ Gentamicin Sulfate Topical Spray Gentamicin Topical Spray Gentocin® Durafilm® Gentocin® Otic Solution Gentocin® Topical Spray Osurnia™ Otomax® Topagen® Ointment Tri-Otic® Ointment VET BETA-GEN® Vetro-Max®

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Cat, Dog, Horse, No Use Class Stated Or Implied

Rx/OTC: RX

Form/route: Gel, Injectable Suspension, Liquid (Solution), Liquid (Suspension), Ointment, Solution, Spray • Intra-Articular, Intramuscular, Ophthalmic, Otic, Topical

Applications: NADA 141-418 • NADA 141-437 • ANADA 200-388 • ANADA 200-229 • ANADA 200-188 • ANADA 200-183 • NADA 140-896 • NADA 49185 • NADA 34010 • ANADA 200-287 • ANADA 200-415 • ANADA 200-416 • NADA 34267 • NADA 46821 • NADA 132-338 • NADA 113-231 • ANADA 200-283

Documents: 16 (FOI: 15) • SPL: 17 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 8 • Cat 8 • View

Case summaries: 10 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Dystocia Lameness (undifferentiated) Metritis Osteoarthritis (Degenerative Joint Disease) Osteoarthritis (Degenerative Joint Disease) Otitis Externa (Ear Infection) Pain (acute, chronic) Pruritus (itching, undifferentiated)

Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

ICD10_CM: H60.90 ICD10_CM: M19.90

Otitis externa, unspecified ear

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Not for use in horses intended or food. For use only by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)

Top reaction signals

Abnormal cytology (1) Abnormal pupil light reflex (1) Abscess NOS (1) Application site alopecia (1) Application site bleeding (1) Application site crust (1) Application site dermatitis (1) Application site erythema (1) Application site fibrosis (1) Application site pruritus (1) Application site scab (1) Application site self trauma (1) Application site ulcer (1) Ataxia (1) Behavioural disorder NOS (1) Behavioural disorder NOS (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
0061-0100-01	0061	-
0061-0387-01	0061	-
0061-0387-02	0061	-
0061-0387-03	0061	-
0061-0387-08	0061	-
0061-0387-17	0061	-
10797-720-01	10797	-
17033-277-02	17033	-
17033-277-20	17033	-
17033-283-02	17033	-
17033-283-20	17033	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

N-141418-C-0022-NF-AA_PI.pdf • Official label • Official • Oct. 25, 2021
FDA official labeling for application 141418
UCM433794.pdf • FOI summary • Official • Oct. 25, 2021
FDA FOI summary for application 141418
UCM436650.pdf • FOI summary • Official • Aug. 11, 2020
FDA FOI summary for application 141437
UCM167677.pdf • FOI summary • Official • Oct. 1, 2019
FDA FOI summary for application 200388
A200229_Orig_4_4_1998.pdf • FOI summary • Official • July 12, 2017
FDA FOI summary for application 200229
UCM061643.pdf • FOI summary • Official • July 12, 2017
FDA FOI summary for application 200229
A200188_Org_1_29_97.pdf • FOI summary • Official • May 22, 2017
FDA FOI summary for application 200188
A200183_Org_7_31_1995.pdf • FOI summary • Official • May 22, 2017
FDA FOI summary for application 200183
N140896_Org_6_9_1993.pdf • FOI summary • Official • May 17, 2017
FDA FOI summary for application 140896
UCM292007.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200416
ucm061352.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200415
ucm061714.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200287
ucm061715.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200287
ucm061716.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200287
ucm061711.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200283
UCM436590.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 34267

Data Sources & Revision History

Every non-trivial field is expected to include provenance and update timestamps.

Official 19 Clinical 0 Manufacturer 0 Marketing 0

Current Field Facts

contraindications: Not for use in horses intended or food. For use only by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order o… (Official, 2026-02-12)
side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Loss of hearing, Ear discharge, Vomiting, Deafness, Hearing decreased. (Official, 2026-02-12)
usage: It is used or intended for use for the treatment of various inflammatory joint conditions; for example, acute and traumatic lameness involving the carpel and f… (Official, 2026-02-12)

Recent Revisions

side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
BetaVet® RX Betamethasone Acetate Betamethasone Sodium Phosphate Injectable Suspension • Intra-Articular Label highlights Official documents	American Regent, Inc.	NADA 141-418	Approved	Oct 25, 2021
Osurnia™ RX Betamethasone Acetate Florfenicol Terbinafine Gel • Otic Label highlights Official documents	Dechra, Ltd.	NADA 141-437	Approved	Aug 11, 2020
GB Topical Spray RX Betamethasone Valerate Gentamicin Sulfate Liquid (Solution) • Topical Label highlights Official documents	Dechra Veterinary Products LLC	ANADA 200-388	Approved	Oct 1, 2019
Tri-Otic® Ointment RX Betamethasone Valerate Clotrimazole Gentamicin Sulfate Ointment • Topical Label highlights Official documents	Med-Pharmex, Inc.	ANADA 200-229	Approved	Jul 12, 2017
Betagen™ Topical Spray RX Betamethasone Valerate Gentamicin Sulfate Spray • Topical Label highlights Official documents	Med-Pharmex, Inc.	ANADA 200-188	Approved	May 22, 2017
VET BETA-GEN® RX Betamethasone Valerate Gentamicin Sulfate Liquid (Solution) • Topical Label highlights Official documents	Med-Pharmex, Inc.	ANADA 200-183	Approved	May 22, 2017
Otomax® RX Betamethasone Valerate Clotrimazole Gentamicin Sulfate Ointment • Topical Label highlights Official documents	Intervet, Inc.	NADA 140-896	Approved	May 17, 2017
Betasone Aqueous Suspension RX Betamethasone Dipropionate Betamethasone Sodium Phosphate Liquid (Suspension) • Intra-Articular, Intramuscular Label highlights Official documents	Intervet, Inc.	NADA 49185	Approved	Jun 1, 2016
Betavet Soluspan Suspension RX Betamethasone Acetate Betamethasone Sodium Phosphate Liquid (Suspension) • Intra-Articular Label highlights Official documents	Intervet, Inc.	NADA 34010	Approved	Jun 1, 2016
GBC Ointment™ RX Betamethasone Valerate Clotrimazole Gentamicin Sulfate Ointment • Topical Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	ANADA 200-287	Approved	Jun 1, 2016
Gentamicin Sulfate Topical Spray RX Betamethasone Valerate Gentamicin Sulfate Spray • Topical Label highlights Official documents	First Priority, Inc.	ANADA 200-415	Approved	Jun 1, 2016
Gentamicin Topical Spray RX Betamethasone Valerate Gentamicin Sulfate Spray • Topical Label highlights Official documents	Sparhawk Laboratories, Inc.	ANADA 200-416	Approved	Jun 1, 2016
Gentocin® Durafilm® RX Betamethasone Acetate Gentamicin Sulfate Solution • Ophthalmic Label highlights Official documents	Intervet, Inc.	NADA 34267	Approved	Jun 1, 2016
Gentocin® Otic Solution RX Betamethasone Valerate Gentamicin Sulfate Liquid (Solution) • Topical Label highlights Official documents	Intervet, Inc.	NADA 46821	Approved	Jun 1, 2016
Gentocin® Topical Spray RX Betamethasone Valerate Gentamicin Sulfate Spray • Topical Label highlights Official documents	Intervet, Inc.	NADA 132-338	Approved	Jun 1, 2016
Topagen® Ointment RX Betamethasone Valerate Gentamicin Sulfate Ointment • Topical Label highlights Official documents	Intervet, Inc.	NADA 113-231	Approved	Jun 1, 2016
Vetro-Max® RX Betamethasone Valerate Clotrimazole Gentamicin Sulfate Ointment • Topical Label highlights Official documents	Fougera Pharmaceuticals, Inc.	ANADA 200-283	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: No Use Class Stated Or Implied

Composition / specifications

6 mg/mL as 3.15 mg betamethasone sodium phosphate and 2.85 mg betamethasone acetate

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

Using strict aseptic technique, administer 1.5 mL BetaVet ® (9 mg total betamethasone) per joint by intra-articular injection. BetaVet ® may be administered concurrently in up to 2 joints per horse.

Limitations

Do not use in horses intended for human consumption.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

10 mg florfenicol, 10 mg terbinafine, and 1 mg betamethasone acetate per mL

Dogs

Indication

For the treatment of otitis externa in dogs associated with susceptible strains of bacteria (Staphylococcus pseudintermedius) and yeast (Malassezia pachydermatis).

Dosage

Administer one dose (1 tube) per affected ear(s) and repeat administration in 7 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Amount: Each mL contains: gentamicin sulfate, USP equivalent to 0.57 mg gentamicin base and betamethasone valerate, USP equivalent to 0.284 mg betamethasone.

Dogs

Indication

For the treatment of infected superficial lesions in dogs caused by bacteria susceptible to gentamicin.

Dosage

Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. Administer 2 to 4 times daily for 7 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy

Composition / specifications

Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams gentamicin base, betamethasone valerate equivalent to 1 milligram betamethasone, and 10 milligrams clotrimazole.

Dogs

Indication

The drug is used for the treatment of canine otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis), and/or bacteria susceptible to gentamicin.

Dosage

From 7.5- or 15-g tube; 10-, 15-, or 25-g bottles install 4 drops of ointment twice daily into the ear canal of dogs weighing less than 30 pounds, instill 8 drops twice daily for dogs weighing 30 pounds or more. From 215-g bottle, instill 2 drops of ointment twice daily into the ear canal of dogs weighing less than 30 pounds, instill 4 drops twice daily for dogs weighing 30 pounds or more. Therapy should continue for 7 consecutive days. The external ear should be cleaned and dried before treatment. Remove foreign material, debris, crusted exudates, etc. with suitable solutions. Excessive hair should be clipped from the treatment area. If hypersensitivity occurs, treatment should be discontinued and alternate therapy instituted.

Limitations

Corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition, followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of spray contains gentamicin sulfate equivalent to 0.57 milligram of gentamicin base and betamethasone valerate equivalent to 0.284 milligram of betamethasone.

Dogs

Indication

The drug is used in dogs in the treatment of infected superficial lesions caused by bacteria sensitive to gentamicin.

Dosage

The lesion and adjacent area should be properly cleaned before treatment. Excessive hair should be removed. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. One actuation of the sprayer delivers 0.7 milliliter of the spray. The drug should be administered with two spray actuations 2 to 4 times daily for 7 days.

Limitations

If hypersensitivity to any of the components occurs treatment should be discontinued and appropriate therapy instituted. The antibiotic susceptibility of the pathogenic organism should be determined prior to use of this preparation. Administration of recommended doses beyond 7 days may result in delayed wound healing. Animals treated longer than 7 days should be monitored closely. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each cubic centimeter of solution contains gentamicin sulfate equivalent to 3 milligrams of gentamicin base and betamethasone valerate equivalent to 1 milligram of betamethasone alcohol.

Dogs

Indication

For the treatment of acute and chronic canine otitis externa caused by bacteria sensitive to gentamicin

Dosage

The drug is administered by instillation of 3 to 8 drops of solution into the ear canal twice daily for 7 to 14 days. Duration of treatment will depend upon the severity of the condition and the response obtained. The duration of treatment and/or frequency of the dosage may be reduced but care should be taken not to discontinue therapy prematurely. The external ear and ear canal should be properly cleaned and dried before treatment. Remove foreign material, debris, crusted exudates, etc., with suitable nonirritating solutions. Excessive hair should be clipped from the treatment area of the external ear.

Limitations

If hypersensitivity to any of the components occurs treatment with this product should be discontinued and appropriate therapy instituted. Concomitant use with other drugs known to induce ototoxicity is not recommended. This preparation should not be used in conditions where corticosteroids are contraindicated. Do not administer parenteral corticosteroids during treatment with this drug. The antibiotic sensitivity of the pathogenic organism should be determined prior to use of this preparation. For use by or on the order of a licensed veterinarian.

Dogs

Indication

For the treatment of canine superficial infected lesions caused by bacteria sensitive to gentamicin.

Dosage

The lesion and adjacent area should be properly cleaned before treatment. Excessive hair should be removed. A sufficient amount of the drug should be applied to cover the treatment area. The drug should be administered twice daily for 7 to 14 days.

Limitations

Cats

Indication

For the treatment of acute and chronic canine otitis externa caused by bacteria sensitive to gentamicin.

Dosage

Limitations

Cats

Indication

For the treatment of feline superficial infected lesions caused by bacteria sensitive to gentamicin.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams gentamicin base, betamethasone valerate equivalent to 1 milligrams betamethasone, and 10 milligrams clotrimazole.

Dogs

Indication

The drug is used for the treatment of canine otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis), and/or bacteria susceptible to gentamicin.

Dosage

From 215 gram bottle, instill 2 drops of ointment twice daily into the ear canal of dogs weighing less than 30 pounds, instill 4 drops twice daily for dogs weighing 30 pounds or more.

Limitations

Install ointment twice daily into the ear canal. Therapy should continue for 7 consecutive days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indication

The drug is used for the treatment of canine otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis), and/or bacteria susceptible to gentamicin.

Dosage

From 7.5 or 15 gram tubes, install 4 drops of ointment twice daily into the ear canal of dogs weighing less than 30 pounds, instill 8 drops twice daily for dogs weighing 30 pounds or more.

Limitations

Install ointment twice daily into the ear canal. Therapy should continue for 7 consecutive days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy • Horse, Restricted During Pregnancy • Horse, Not For Meat Production

Composition / specifications

Each milliliter of the suspension contains the equivalent of 5 milligrams of betamethasone as betamethasone dipropionate and 2 milligrams of betamethasone as betamethasone sodium phosphate.

Dogs

Indication

It is used as an aid in the control of pruritus associated with dermatoses.

Dosage

It is administered by intramuscular injection at a dosage of 0.25 to 0.5 milliliter per 20 pounds of body weight, depending on the severity of the condition. Frequency of dosage depends on recurrence of pruritic symptoms. Dosage may be repeated every 3 weeks or when symptoms recur, not to exceed a total of 4 injections.

Limitations

It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Horses

Indication

It is used as an aid in the control of inflammation associated with various arthropathies.

Dosage

It is administered aseptically by intraarticular injection at a dosage of 2.5 to 5 milliliters per joint, depending on the severity of the condition and the joint size. Dosage may be repeated upon recurrence of clinical signs. Injection into the joint cavity should be preceded by withdrawal of synovial fluid.

Limitations

Not for use in horses intended for food. It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production

Composition / specifications

The drug is a sterile aqueous suspension and each cubic centimeter contains: 12 milligrams of betamethasone acetate (equivalent to 10.8 milligrams of betamethasone), 3.9 milligrams of betamethasone disodium phosphate (equivalent to 3 milligrams of betamethasone)

Horses

Indication

It is used or intended for use for the treatment of various inflammatory joint conditions; for example, acute and traumatic lameness involving the carpel and fetlock joints.

Dosage

Administer from 2.5 to 5 cubic centimeters per dose by intra-articular injection. Dose may be repeated when necessary depending upon the duration of relief obtained.

Limitations

Not for use in horses intended or food. For use only by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy

Composition / specifications

Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams gentamicin base, betamethasone valerate equivalent to 1 milligrams betamethasone, and 10 milligrams clotrimazole.

Dogs

Indication

For the treatment of acute and chronic canine otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis) and/or bacteria susceptible to gentamicin.

Dosage

Install ointment twice daily into the ear canal. Therapy should continue for 7 consecutive days. From 10-g bottles: 4 drops for dogs weighing less than 30 pounds (lb) or 8 drops for dogs weighing 30 lb or more. From 20-, 40-, or 215-g bottles: 2 drops for dogs weighing less than 30 lb or 4 drops for dogs weighing 30 lb or more.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of spray contains gentamicin sulfate equivalent to 0.57 milligram of gentamicin base and betamethasone valerate equivalent to 0.284 milligram of betamethasone.

Dogs

Indication

The drug is used in dogs in the treatment of infected superficial lesions caused by bacteria sensitive to gentamicin.

Dosage

Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. The drug should be administered with two spray actuations 2 to 4 times daily for 7 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of spray contains gentamicin sulfate, USP equivalent to 0.57 mg of gentamicin base and betamethasone valerate, USP equivalent to 0.284 mg of betamethasone.

Dogs

Indication

For the treatment of infected superficial lesions in dogs caused by bacteria susceptible to gentamicin.

Dosage

Administer two depressions of the sprayer head 2 to 4 times daily for 7 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Label highlights

Indication

For treatment of external eye infections and inflammation in dogs.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains gentamicin sulfate equivalent to 3 milligrams (mg) gentamicin base and betamethasone valerate equivalent to 1 mg betamethasone alcohol.

Dogs

Indication

For the treatment of infected superficial lesions caused by bacteria sensitive to gentamicin.

Dosage

Apply a sufficient amount of the drug to cover the treatment area twice daily for 7 to 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indication

For the treatment of acute and chronic otitis externa caused by bacteria sensitive to gentamicin in dogs.

Dosage

Instill three to eight drops of solution into the ear canal twice daily for 7 to 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

For the treatment of infected superficial lesions caused by bacteria sensitive to gentamicin.

Dosage

Apply a sufficient amount of the drug to cover the treatment area twice daily for 7 to 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of spray contains gentamicin sulfate equivalent to 0.57 milligram of gentamicin base and betamethasone valerate equivalent to 0.284 milligram of betamethasone.

Dogs

Indication

The drug is used in dogs in the treatment of infected superficial lesions caused by bacteria sensitive to gentamicin.

Dosage

For the treatment of infected superficial lesions, the lesion and adjacent area should be properly cleaned before treatment. Excessive hair should be removed. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. One actuation of the sprayer delivers 0.7 milliliter of the spray. The drug should be administered with two spray actuations 2 to 4 times daily for 7 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams of gentamicin base and betamethasone valerate equivalent to 1 milligram of betamethasone.

Dogs

Indication

The drug is used or indicated for canine infected superficial lesions caused by bacteria sensitive to gentamicin.

Dosage

For the treatment of canine infected superficial lesions, the lesion and adjacent area should be properly cleaned before treatment. Excessive hair should be removed. A sufficient amount of the drug should be applied to cover the treatment area. The drug should be administered twice daily for 7 to 14 days.

Limitations

If hypersensitivity to any of the components occurs, treatment should be discontinued and appropriate therapy instituted. Concomitant use of drugs known to induce ototoxicity should be avoided. Observe patients for signs of adrenocorticoid overdosage. The antibiotic susceptibility of the pathogenic organism should be determined prior to use of this preparation. Administration of recommended doses beyond 7 days may result in delayed wound healing. Animals treated longer than 7 days should be monitored closely. For use by or on the order of a licensed veterinarian.

Indication

The drug is used or indicated for use in dogs in the treatment of acute and chronic canine otitis externa.

Dosage

For the treatment of acute and chronic canine otitis externa the drug is administered by instillation of 3 to 8 drops into the ear canal twice daily for 7 days. The external ear and ear canal should properly cleaned and dried before treatment. Remove foreign material, debris, crusted exudates, etc., with suitable nonirritating solutions. Excessive hair should be clipped from the treatment area of the external ear.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams gentamicin base, betamethasone valerate equivalent to 1 milligrams betamethasone, and 10 milligrams clotrimazole.

Dogs

Indication

The drug is used for the treatment of canine otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis), and/or bacteria susceptible to gentamicin.

Dosage

From 215 gram bottle, instill 2 drops of ointment twice daily into the ear canal of dogs weighing less than 30 pounds, instill 4 drops twice daily for dogs weighing 30 pounds or more.

Limitations

Install ointment twice daily into the ear canal. Therapy should continue for 7 consecutive days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indication

The drug is used for the treatment of canine otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis), and/or bacteria susceptible to gentamicin.

Dosage

From 7.5 or 15 gram tubes, install 4 drops of ointment twice daily into the ear canal of dogs weighing less than 30 pounds, instill 8 drops twice daily for dogs weighing 30 pounds or more.

Limitations

Install ointment twice daily into the ear canal. Therapy should continue for 7 consecutive days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents

FOI UCM433794.pdf

Summary

For the control of pain and inflammation associated with osteoarthritis in horses.
Labeling N-141418-C-0022-NF-AA_PI.pdf

SPL Packages

BetaVet® (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM436650.pdf

Summary

For the treatment of otitis externa in dogs associated with susceptible strains of bacteria ( Staphylococcus pseudintermedius) and yeast ( Malassezia pachydermatis).

SPL Packages

Osurnia™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM167677.pdf

Summary

For the treatment of infected superficial lesions in dogs caused by bacteria susceptible to gentamicin.

SPL Packages

GB Topical Spray (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM061643.pdf

Summary

The addition of a 15 gram bottle package size made from a new material MDPE, instead of the existing LDPE or HDPE used in other sizes.
FOI A200229_Orig_4_4_1998.pdf

Summary

Tri-Otic Ointment is indicated for the treatment of canine acute and chronic otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis) and/or bacteria susceptible to gentamicin.

SPL Packages

Tri-Otic® Ointment (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI A200188_Org_1_29_97.pdf

Summary

For the treatment of infected superficial lesions in dogs caused by bacteria sensitive to gentamicin.

SPL Packages

Betagen™ Topical Spray (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI A200183_Org_7_31_1995.pdf

Summary

For the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin.

SPL Packages

VET BETA-GEN® (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI N140896_Org_6_9_1993.pdf

Summary

OTOMAX is indicated for treatment of canine acute and chronic otitis externa associated with yeast (Malassezia pachydermatis formerly Pityrosporum canis) and/or bacteria susceptible to gentamicin.

SPL Packages

Otomax® (ZIP)

FDA page: Open in Animal Drugs @ FDA

SPL Packages

Betasone Aqueous Suspension (ZIP)

FDA page: Open in Animal Drugs @ FDA

SPL Packages

Betavet Soluspan Suspension (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI ucm061716.pdf

Summary

This application provides for a new container size (40 gram dropper bottle).
FOI ucm061715.pdf

Summary

This supplement provides for an additional package size, 20-gram fill in a 30 mL bottle. The bottle will be the same LDPE as the approved 15 mL bottle, and the plug, dropper and cap will be the exact same closure as the approved package.
FOI ucm061714.pdf

Summary

Treatment of canine acute and chronic otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis) and/or bacteria susceptible to gentamicin

SPL Packages

GBC Ointment™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI ucm061352.pdf

Summary

For the treatment of infected superficial lesions in dogs caused by bacteria susceptible to gentamicin.

SPL Packages

Gentamicin Sulfate Topical Spray (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM292007.pdf

Summary

For the treatment of infected superficial lesions in dogs caused by bacteria susceptible to gentamicin.

SPL Packages

Gentamicin Topical Spray (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM436590.pdf

Summary

This supplement provides for a new product formulation..

SPL Packages

Gentocin® Durafilm® (ZIP)

FDA page: Open in Animal Drugs @ FDA

SPL Packages

Gentocin® Otic Solution (ZIP)

FDA page: Open in Animal Drugs @ FDA

SPL Packages

Gentocin® Topical Spray (ZIP)

FDA page: Open in Animal Drugs @ FDA

SPL Packages

Topagen® Ointment (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI ucm061711.pdf

Summary

For the treatment of canine acute and chronic otitis externa associated with yeast ( Malassezia pachydermatis, formerly Pityrosporum canis) and/or bacteria susceptible to gentamicin.

SPL Packages

Vetro-Max® (ZIP)

FDA page: Open in Animal Drugs @ FDA

Usage

It is used or intended for use for the treatment of various inflammatory joint conditions; for example, acute and traumatic lameness involving the carpel and fetlock joints. For treatment of external eye infections and inflammation in dogs. For the treatment of infected superficial lesions caused by bacteria sensitive to gentamicin.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Side Effects

No approved side-effect narrative is linked yet.

openFDA reaction signals are available for Dog 8 and Cat 8 (view top reported reactions).

Top Reported Reactions (openFDA)

Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).

Dog

Digestive

Vomiting (76)

Neurologic

Tiredness (lethargy) (64)

Effectiveness

Lack of efficacy - NOS (822)

Other

Loss of hearing (94) Ear discharge (84) Deafness (75) Hearing decreased (68) Other abnormal test result NOS (59)

Cat

Digestive

Loss of appetite (17)

Neurologic

Unsteady walking (ataxia) (34)

Effectiveness

Lack of efficacy - NOS (17)

Other

Horner's syndrome (34) Third eyelid protrusion (29) Head tilt - ear disorder (18) Anisocoria (17) Weight loss (17)

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, ['Retriever - Labrador', 'Poodle - Standard'], Male, 6 year • Drug: MSK, Gel, Auricular (Otic), Dose: 1 tube per animal • Reactions: Lack of efficacy - NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-037213
Serious AE: No
Treated For AE: Yes
Sex: Male
Age: 6.00 Year

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Auricular (Otic)
Form: Gel
Dose: 1 tube per animal

Reactions Reported:

Lack of efficacy - NOS

Outcomes: Ongoing

Dog, Shepherd Dog - German, Male, 8 year, 23.13 kilogram • Drug: MSK, Gel, Topical • Reactions: Lack of efficacy - NOS, Ear canal erythema, Ear pain, Ear discharge • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-011509
Serious AE: No
Treated For AE: Yes
Sex: Male
Age: 8.00 Year
Weight: 23.130 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Topical
Form: Gel

Reactions Reported:

Lack of efficacy - NOS Ear canal erythema Ear pain Ear discharge

Outcomes: Outcome Unknown

Dog, Crossbred Canine/dog, Male, 8.5 year • Drug: MSK, Gel, Unknown • Reactions: Lack of efficacy - NOS, Head shake - ear disorder, Eye redness, Ocular discharge, Behavioral disorder (unspecified)… • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-007614
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 8.50 Year

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Gel

Reactions Reported:

Lack of efficacy - NOS Head shake - ear disorder Eye redness Ocular discharge Behavioral disorder (unspecified) Eye irritation Not eating Heart murmur Tooth disorder Facial paralysis Impaired hearing Head tilt - neurological disorder Abnormal pupil light reflex Depressed ocular reflex Blinking Drooping eyelid Excessive ear wax Ear infection NOS Otitis NOS

Outcomes: Outcome Unknown

Dog, Shepherd Dog - German, Male, 1 year, 35.3 kilogram • Drug: MSK, Gel, Unknown • Reactions: Lack of efficacy (fungi) - NOS • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2024-US-059166
Serious AE: No
Treated For AE: Yes
Sex: Male
Age: 1.00 Year
Weight: 35.300 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Gel

Reactions Reported:

Lack of efficacy (fungi) - NOS

Outcomes: Outcome Unknown

Dog, Retriever - Labrador, Female, 13 year, 33.3 kilogram • Drug: MSK, Ointment, Auricular (Otic), Dose: 1 dose per other, Frequency: 12 per hour • Reactions: Loss of hearing • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2024-US-064354
Serious AE: No
Treated For AE: No
Sex: Female
Age: 13.00 Year
Weight: 33.300 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Auricular (Otic)
Form: Ointment
Dose: 1 dose per other
Frequency: 12 per hour

Reactions Reported:

Loss of hearing

Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Male, 5 year, 8.074 kilogram • Drug: MSK, Unknown • Reactions: Vomiting, Abscess NOS, Polyuria, Polydipsia, Neutrophilia… • Outcome: Ongoing

Report ID: USA-USFDACVM-2024-US-026147
Serious AE: No
Treated For AE: Yes
Sex: Male
Age: 5.00 Year
Weight: 8.074 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Vomiting Abscess NOS Polyuria Polydipsia Neutrophilia Glucosuria Hyperglycaemia Elevated alanine aminotransferase Hyperproteinaemia Elevated globulins Elevated blood urea nitrogen

Outcomes: Ongoing

Cat, Domestic Mediumhair, Female, 3.5 year, 4.082 kilogram • Drug: MSK, Gel, Auricular (Otic) • Reactions: Unsteady walking (ataxia), Other ear disorder NOS, Ear canal erythema, Not eating, Vomiting… • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2022-US-000703
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 3.50 Year
Weight: 4.082 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Auricular (Otic)
Form: Gel

Reactions Reported:

Unsteady walking (ataxia) Other ear disorder NOS Ear canal erythema Not eating Vomiting Tympanic alteration Tympanic rupture Pain NOS

Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Male, 7 year, 6.35 kilogram • Drug: MSK, Subcutaneous, Dose: 1 dose per unknown, Frequency: 1 per day • Reactions: Inappropriate urination, Application site pruritus, Application site erythema, Hair loss at application site, Application site ulcer… • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2020-US-055851
Serious AE: No
Treated For AE: No
Sex: Male
Age: 7.00 Year
Weight: 6.350 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Dose: 1 dose per unknown
Frequency: 1 per day

Reactions Reported:

Inappropriate urination Application site pruritus Application site erythema Hair loss at application site Application site ulcer Application site crust Application site bleeding Application site self trauma Abnormal cytology Application site scab Application site dermatitis Application site fibrosis Inappropriate elimination NOS

Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on PetWisePlus are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Betamethasone

Pet Owner Quick Guide

Betamethasone

Quick Facts

Warnings / Contraindications

Adverse Reactions

Most Reported Reactions

Storage & Handling

Documents

Promotional Materials (Marketing)

At a Glance

Counseling and Monitoring Highlights

Identifiers & Packages

Enriched Documents

Data Sources & Revision History

FDA Products & Applications (Animal Drugs @ FDA)

What It's For (FDA Label Highlights)

BetaVet® • Injectable Suspension • Intra-Articular

Osurnia™ • Gel • Otic

GB Topical Spray • Liquid (Solution) • Topical

Tri-Otic® Ointment • Ointment • Topical

Betagen™ Topical Spray • Spray • Topical

VET BETA-GEN® • Liquid (Solution) • Topical

Otomax® • Ointment • Topical

Betasone Aqueous Suspension • Liquid (Suspension) • Intra-Articular, Intramuscular

Betavet Soluspan Suspension • Liquid (Suspension) • Intra-Articular

GBC Ointment™ • Ointment • Topical

Gentamicin Sulfate Topical Spray • Spray • Topical

Gentamicin Topical Spray • Spray • Topical

Gentocin® Durafilm® • Solution • Ophthalmic

Gentocin® Otic Solution • Liquid (Solution) • Topical

Gentocin® Topical Spray • Spray • Topical

Topagen® Ointment • Ointment • Topical

Vetro-Max® • Ointment • Topical

Official Documents (FDA)

BetaVet® • 141418

Osurnia™ • 141437

GB Topical Spray • 200388

Tri-Otic® Ointment • 200229

Betagen™ Topical Spray • 200188

VET BETA-GEN® • 200183

Otomax® • 140896

Betasone Aqueous Suspension • 49185

Betavet Soluspan Suspension • 34010

GBC Ointment™ • 200287

Gentamicin Sulfate Topical Spray • 200415

Gentamicin Topical Spray • 200416

Gentocin® Durafilm® • 34267

Gentocin® Otic Solution • 46821

Gentocin® Topical Spray • 132338

Topagen® Ointment • 113231

Vetro-Max® • 200283

Usage

Contraindications

Side Effects

Top Reported Reactions (openFDA)

Adverse Event Case Summaries (openFDA)

Jun 23, 2025 • Dog • ['Retriever - Labrador', 'Poodle - Standard'] • Lack of efficacy - NOS • Ongoing

Feb 21, 2025 • Dog • Shepherd Dog - German • Lack of efficacy - NOS, Ear canal erythema • Outcome Unknown

Feb 12, 2025 • Dog • Crossbred Canine/dog • Lack of efficacy - NOS, Head shake - ear disorder • Outcome Unknown

Sep 19, 2024 • Dog • Shepherd Dog - German • Lack of efficacy (fungi) - NOS • Outcome Unknown

Sep 13, 2024 • Dog • Retriever - Labrador • Loss of hearing • Outcome Unknown

May 7, 2024 • Cat • Domestic Shorthair • Vomiting, Abscess NOS • Ongoing

Jan 5, 2022 • Cat • Domestic Mediumhair • Unsteady walking (ataxia), Other ear disorder NOS • Outcome Unknown

Oct 27, 2020 • Cat • Domestic Shorthair • Inappropriate urination, Application site pruritus • Outcome Unknown

Overdose Information

Storage & Handling

Share Your Thoughts